August 22, 2008 — Concomitant zoledronic acid (Zometa, Novartis) that is given during adjuvant endocrine therapy can prevent bone loss in premenopausal breast cancer patients. It also improves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results